title: Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?
authors: Department of Hematology, A.O. Sant’Andrea, University La Sapienza, Rome, Italy. chrisscox@gmail.com
authors: Maria Christina
authors: MC
authors: Cox
authors: Giuseppe
authors: G
authors: Mannino
authors: Luana
authors: L
authors: Lionetto
authors: Virginia
authors: V
authors: Naso
authors: Maurizio
authors: M
authors: Simmaco
authors: Maria Antonietta Aloe
authors: MA
authors: Spiriti
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D002853:Chromatography, Liquid; D006801:Humans; D000077269:Lenalidomide; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D009915:Orbit / Q000187:drug effects* / Q000473:pathology; D053719:Tandem Mass Spectrometry; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide